Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common stock, $.01 par value per share
-
Shares outstanding
-
46,791,479
-
Total 13F shares
-
50,568,886
-
Share change
-
-213,520
-
Total reported value
-
$4,325,205,912
-
Put/Call ratio
-
43%
-
Price per share
-
$85.51
-
Number of holders
-
294
-
Value change
-
-$20,996,057
-
Number of buys
-
119
-
Number of sells
-
154
Institutional Holders of HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) as of Q4 2023
As of 31 Dec 2023,
HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) was held by
294 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,568,886 shares.
The largest 10 holders included
Capital Research Global Investors, BlackRock Inc., VANGUARD GROUP INC, NEUBERGER BERMAN GROUP LLC, WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, FRANKLIN RESOURCES INC, FMR LLC, T. Rowe Price Investment Management, Inc., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
294
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.